These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26371421)

  • 1. Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.
    Pinciroli P; Won H; Iyer G; Canevari S; Colecchia M; Giannatempo P; Raggi D; Pierotti MA; De Braud FG; Solit DB; Rosenberg JE; Berger MF; Necchi A
    Clin Genitourin Cancer; 2016 Feb; 14(1):e81-90. PubMed ID: 26371421
    [No Abstract]   [Full Text] [Related]  

  • 2. Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
    Palma N; Morris JC; Ali SM; Ross JS; Pal SK
    Eur Urol; 2015 Jul; 68(1):168-70. PubMed ID: 25766722
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel.
    Jackson-Spence F; Ackerman C; Jones R; Toms C; Jovaisaite A; Young M; Hussain S; Protheroe A; Birtle A; Chakraborti P; Huddart R; Jagdev S; Bahl A; Sundar S; Crabb S; Powles T; Szabados B
    Urol Oncol; 2024 Nov; 42(11):372.e1-372.e10. PubMed ID: 39025719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
    Xu CF; Bing NX; Ball HA; Rajagopalan D; Sternberg CN; Hutson TE; de Souza P; Xue ZG; McCann L; King KS; Ragone LJ; Whittaker JC; Spraggs CF; Cardon LR; Mooser VE; Pandite LN
    J Clin Oncol; 2011 Jun; 29(18):2557-64. PubMed ID: 21576632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
    Bellmunt J; Lalani AA; Jacobus S; Wankowicz SA; Polacek L; Takeda DY; Harshman LC; Wagle N; Moreno I; Lundgren K; Bossé D; Van Allen EM; Choueiri TK; Rosenberg JE
    Br J Cancer; 2018 Sep; 119(6):707-712. PubMed ID: 30220708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of refractory Ewing sarcoma to pazopanib.
    Alcindor T
    Acta Oncol; 2015 Jul; 54(7):1063-4. PubMed ID: 25345493
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy.
    Gerullis H; Eimer C; Ecke TH; Georgas E; Arndt C; Otto T
    Anticancer Drugs; 2013 Apr; 24(4):422-5. PubMed ID: 23407060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
    Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
    Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
    Arai H; Fukasawa N; Ueta F
    Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):37-42. PubMed ID: 23302947
    [No Abstract]   [Full Text] [Related]  

  • 10. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
    Wagle N; Grabiner BC; Van Allen EM; Hodis E; Jacobus S; Supko JG; Stewart M; Choueiri TK; Gandhi L; Cleary JM; Elfiky AA; Taplin ME; Stack EC; Signoretti S; Loda M; Shapiro GI; Sabatini DM; Lander ES; Gabriel SB; Kantoff PW; Garraway LA; Rosenberg JE
    Cancer Discov; 2014 May; 4(5):546-53. PubMed ID: 24625776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib in ovarian cancer.
    McLachlan J; Banerjee S
    Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
    Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
    Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
    Verweij J; Sleijfer S
    Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarkers in bladder cancer.
    Cheng ML; Iyer G
    Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib for the treatment of breast cancer.
    Amiri-Kordestani L; Tan AR; Swain SM
    Expert Opin Investig Drugs; 2012 Feb; 21(2):217-25. PubMed ID: 22233389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib in the treatment of soft tissue sarcoma.
    Schöffski P
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-ErbB targeted therapy and urothelial tumors].
    Amsellem-Ouazana D; Goldwasser F; Bieche I; Lidereau R; Zerbib M
    Prog Urol; 2005 Dec; 15(6 Suppl 1):1229-35. PubMed ID: 16734210
    [No Abstract]   [Full Text] [Related]  

  • 18. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma.
    Fujita M; Endo Y; Fujisawa A; Tanioka M; Kabashima K; Miyachi Y
    Eur J Dermatol; 2014; 24(2):267-8. PubMed ID: 24682601
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting Signaling Transduction Pathways in Bladder Cancer.
    Abbosh PH; McConkey DJ; Plimack ER
    Curr Oncol Rep; 2015 Dec; 17(12):58. PubMed ID: 26472299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 and treatment of bladder cancer.
    Cote RJ; Esrig D; Groshen S; Jones PA; Skinner DG
    Nature; 1997 Jan; 385(6612):123-5. PubMed ID: 8990112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.